Delcath Systems’ $22 Million Public Offering

Lowenstein Sandler represented Delcath Systems, Inc. on the deal.

Delcath Systems, Inc. (OTCQB:DCTH NASDAQ:DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, completed a $22 million underwritten public offering of shares and warrants that closed on May 5, 2020.

In connection with the offering, Delcath’s common stock was approved for listing on the Nasdaq Capital Market and began trading on the Nasdaq Capital Market under the symbol “DCTH” on May 1, 2020.

Delcath intends to use the net proceeds of the offering for working capital and general corporate purposes, including the continued development of Melphalan/HDS.

Roth Capital Partners acted as sole book-running manager for the offering. Aegis Capital Corp. and Laidlaw & Company (UK) Ltd. acted as co-lead managers for the offering.

The Lowenstein Sandler deal team advising Delcath Systems included John D. “Jack” Hogoboom (Picture), Robert J. Paradiso, Brian A. Silikovitz, James C. Shehan, Sarah P. Cole, Michael T. Melchiorre, Erica Perlmutter, and Kristin V. Taylor.

Involved fees earner: Sarah Cole – Lowenstein Sandler LLP; John Hogoboom – Lowenstein Sandler LLP; Michael Melchiorre – Lowenstein Sandler LLP; Robert Paradiso – Lowenstein Sandler LLP; Erica Perlmutter – Lowenstein Sandler LLP; James Shehan – Lowenstein Sandler LLP; Brian Silikovitz – Lowenstein Sandler LLP; Kristin Taylor – Lowenstein Sandler LLP;

Law Firms: Lowenstein Sandler LLP;

Clients: Delcath Systems;

Author: Ambrogio Visconti